- Home
- NFE vs IRON Comparison
NFE vs IRON Comparison
Compare NFE & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NFE
- IRON
- Stock Information
- Founded
- NFE 2014
- IRON 2017
- Country
- NFE United States
- IRON United States
- Employees
- NFE N/A
- IRON N/A
- Industry
- NFE Oil/Gas Transmission
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- NFE Utilities
- IRON Health Care
- Exchange
- NFE Nasdaq
- IRON Nasdaq
- Market Cap
- NFE 1.6B
- IRON 1.4B
- IPO Year
- NFE 2019
- IRON N/A
- Fundamental
- Price
- NFE $6.32
- IRON $44.24
- Analyst Decision
- NFE Buy
- IRON Strong Buy
- Analyst Count
- NFE 6
- IRON 10
- Target Price
- NFE $15.17
- IRON $83.80
- AVG Volume (30 Days)
- NFE 6.3M
- IRON 403.4K
- Earning Date
- NFE 05-12-2025
- IRON 05-07-2025
- Dividend Yield
- NFE 3.17%
- IRON N/A
- EPS Growth
- NFE N/A
- IRON N/A
- EPS
- NFE N/A
- IRON N/A
- Revenue
- NFE $2,354,111,000.00
- IRON N/A
- Revenue This Year
- NFE $6.75
- IRON N/A
- Revenue Next Year
- NFE $24.11
- IRON N/A
- P/E Ratio
- NFE N/A
- IRON N/A
- Revenue Growth
- NFE N/A
- IRON N/A
- 52 Week Low
- NFE $4.72
- IRON $28.25
- 52 Week High
- NFE $29.11
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- NFE 49.34
- IRON 45.99
- Support Level
- NFE $5.50
- IRON $40.36
- Resistance Level
- NFE $6.26
- IRON $47.21
- Average True Range (ATR)
- NFE 0.42
- IRON 2.87
- MACD
- NFE 0.25
- IRON 0.10
- Stochastic Oscillator
- NFE 97.03
- IRON 37.67
About NFE New Fortress Energy Inc.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.